Moderna, Inc.

NASDAQ: MRNA
$69.47
+$4.30 (+6.6%)
Closing price September 25, 2020
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
Tuesday's top analyst upgrades and downgrades include Apple, Baidu, Boeing, Delta Air Lines, L3Harris Technologies, Moderna, Raytheon Technologies, Roku and Walt Disney.
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Independent research firm Argus has reiterated its Buy rating on Moderna and is calling this large pullback a buying opportunity.
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Thursday's top analyst upgrades and downgrades included Apache, Check Point Software Technologies, Chipotle Mexican Grill, Electronic Arts, Inogen, Microsoft, Moderna, Shopify, Tesla and Varonis...
These four top Jefferies growth stock picks all offer investors strength in their specific industries and the ability to generate some significant portfolio alpha.
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how...
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see a big...
Moderna made another big step forward in the fight against COVID-19 after the company reported incredibly positive data from the early-stage trial of its coronavirus vaccine.